Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Filgrastim Hospira vs Neupogen in Healthy Volunteers
NCT02766647Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Pfizer. Primary endpoints: Area under the serum filgrastim concentration versus time curve from zero to infinity at 48 hours, Maximum serum filgrastim concentration at 48 hours and 2 more. Started Dec 2015; status: completed.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02766647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766647.